Advertisement

Topics

Ocular Therapeutix, Inc. Company Profile

11:31 EST 17th December 2018 | BioPortfolio

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix is focusing on development of drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and ReSure® Sealant for sealing clear corneal incisions following lens implantation surgery.


News Articles [137 Associated News Articles listed on BioPortfolio]

Ocular Therapeutix files third NDA for ocular pain drug

A new drug application was filed for the third time by Ocular Therapeutix for Dextenza, or dexamethasone insert, 0.4 mg to tr -More- 

Ocular Therapeutix Announces NDA Resubmission of DEXTENZA

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announc...

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced th...

FDA issues warning letter to Ocular Therapeutix over ReSure sealant

The letter relates to Ocular’s compliance with data collection and information reporting obligations in a post-approval Device Exposure Registry study required as a condition for approval of the Th...

FDA Approves Treatment for Ocular Pain Following Surgery

NewsDextenza has the potential to replace a complex eye drop regimen that under the current standard of care requires up to 70 topical ocular steroid drops.

Ocular Therapeutix™ to Present at the 2018 JMP Securities Life Sciences Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and condition...

Ocular Therapeutix™ to Present at the 30th Annual Piper Jaffray Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditio...

Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditio...

PubMed Articles [598 Associated PubMed Articles listed on BioPortfolio]

Corneal fluorescein staining and ocular symptoms but not Schirmer test are useful as indicators of response to treatment in chronic ocular GVHD.

To evaluate long-term ocular surface clinical signs and symptoms response to therapy in patients with chronic ocular GVHD.

Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Dry eye disease (DED) of ocular graft-versus-host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). Ongoing inflammation and irreversible fibroti...

Elevated Tear Human Neutrophil Peptides 1-3, Human Beta Defensin-2 Levels and Conjunctival Cathelicidin LL-37 Gene Expression in Ocular Rosacea.

To investigate the role of innate immunity in ocular rosacea.

Ocular Whipple Disease: Report of Three Cases.

To emphasize the different manifestations of ocular involvement in Whipple disease with challenge in establishing the diagnosis as clinical, laboratory, and histological features could mimic other uve...

Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Until recently, the ocular surface is thought by many to be sterile and devoid of living microbes. It is now becoming clear that this may not be the case. Recent and sophisticated PCR analyses have sh...

Clinical Trials [832 Associated Clinical Trials listed on BioPortfolio]

A Retrospective Study of the Effects of Ocular Acupuncture on Ocular Motor Nerve Palsy

This retrospective observational study is designed to assess the response to treatment with ocular acupuncture and its relative factors, in terms of diplopia status, ocular motility differ...

Ocular Coil Drug Delivery Comfort Trial

The Ocular Coil is intended to provide drug delivery to the ocular surface. This study will evaluate the safety and tolerability of the placebo Ocular Coil in healthy subjects.

Surveillance of Ocular Surface Flora (SURFACE)

Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections. The present study is set to determine the bacteri...

The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow

Objectives: To determine LYC-001e's influences on ocular blood flow Ocular blood flow has been implicated as a parameter relevant to eye health and involved in the disease process of sever...

Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy

Dry eye disease (DED), as one of the most common ocular surface diseases that affecting visual acuity, is highly associated with ocular surface inflammation. Until now, there is no accurat...

Companies [69 Associated Companies listed on BioPortfolio]

Ocular Therapeutix, Inc. 

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of t...

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietar...

Ora, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its p...

Ocular Therapeutix™, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the ...

I-Therapeutix, Inc.

More Information about "Ocular Therapeutix, Inc." on BioPortfolio

We have published hundreds of Ocular Therapeutix, Inc. news stories on BioPortfolio along with dozens of Ocular Therapeutix, Inc. Clinical Trials and PubMed Articles about Ocular Therapeutix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ocular Therapeutix, Inc. Companies in our database. You can also find out about relevant Ocular Therapeutix, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Anesthesiology
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...


Corporate Database Quicklinks



Searches Linking to this Company Record